Radiopharm Theranostics, Ltd
Clinical trials sponsored by Radiopharm Theranostics, Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New radioactive tracer could spot hidden tumors Results expected Sep 2026 (estimated)
- New radioactive antibody could light up Hard-to-Treat cancers Results expected Aug 2027 (estimated)
-
Radioactive antibody targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called 161Tb-RAD402 in 73 men with castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The drug is a radioactive antibody designed to seek out and attack cancer cells by targeting a protein called fr…
Phase 1/2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…
Phase 1/2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Radioactive 'Smart Bomb' targets cancer in new human trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…
Early phase 1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
Disease control Recruiting nowThis early-phase trial tests a new drug called 177Lu-RAD202, which is a radioactive antibody designed to seek out and deliver radiation directly to HER2-positive cancer cells. The study involves 30 adults with advanced solid tumors that have not responded to standard treatments. …
Early phase 1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC